Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres | Zendy

Ursula Vogl | Zendy; Laurenz Vormittag | Zendy; Thomas Winkler | Zendy; Alice Kafka | Zendy; Olivia Weiser-Jasch | Zendy; Bettina Heinrich | Zendy; Sophie RoiderSchur | Zendy; Haleh Andalibi | Zendy; Eva Maria Autzinger | Zendy; Wolfgang Schima | Zendy; Alexander Klaus | Zendy; Johannes Zacherl | Zendy; Günter Michael Wimberger | Zendy; Leopold Öhler | Zendy

Open Access

Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres

Author(s) -

Ursula Vogl,

Laurenz Vormittag,

Thomas Winkler,

Alice Kafka,

Olivia Weiser-Jasch,

Bettina Heinrich,

Sophie RoiderSchur,

Haleh Andalibi,

Eva Maria Autzinger,

Wolfgang Schima,

Alexander Klaus,

Johannes Zacherl,

Günter Michael Wimberger,

Leopold Öhler

Publication year - 2020

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2020.03.10

Subject(s) - ramucirumab , medicine , folfiri , paclitaxel , refractory (planetary science) , gastroesophageal junction , oncology , gastric adenocarcinoma , metastatic adenocarcinoma , gastroenterology , adenocarcinoma , cancer , oxaliplatin , physics , colorectal cancer , astrobiology

Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- and 5-FU-containing chemotherapy (CHT) regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research